Most-Favored-Nation
Coverage of Most-Favored-Nation in the Nexus archive.
- Trump slashes Medicare drug subsidies, cutting against affordability message
The end of a Medicare drug subsidy program may increase costs for seniors, conflicting with President Trump's claims about lowering drug prices through TrumpRx and 'most-favored-nation' agreements.
- Trump slashes Medicare drug subsidies, cutting against affordability message
President Trump's elimination of a Medicare drug subsidy program could increase monthly costs for millions of seniors, conflicting with his stated goals of reducing drug prices. The move contradicts Trump's promotion of initiatives like the TrumpRx platform and 'most-favored-nation' deals aimed at lowering drug costs.
- Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
President Donald Trump announced a deal with Regeneron Pharmaceuticals to lower drug prices under the most-favored-nation initiative, including discounted Medicaid pricing and a $225 price for cholesterol drug Praluent on the TrumpRx website. The agreement, part of broader efforts to reduce healthcare costs ahead of midterms, also includes $27 billion in U.S. R&D investments and expedited FDA approval for Regeneron's gene therapy.